A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma
This phase 1b/2 trial studies the safety and best dose of lenalidomide when given together with MIL62 and how well this combination works in treating patients with Relapsed/Refractory low-grade Follicular Lymphoma(FL) and Marginal Zone Lymphoma(MZL). Giving MIL62 plus lenalidomide may work better in indolent Non-Hodgkin Lymphoma(NHL).
• Adult patients, \>=18 years of age;
• Patients with either histologically documented CD20-positive MZL or FL, WHO grade 1, 2 or 3a
• Evidence of progression or lack of response following at least 1 prior treatment
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
• At least one bi-dimensionally measurable nodal or tumor lesion defined by CT scan as: greatest transverse diameter \> 1.5 cm and a short axis ≥ 10mm
• Adequate hematologic function (unless abnormalities are related to NHL)
• Life expectancy \>6 months
• Able and willing to provide written informed consent and to comply with the study protocol